← Back to Search

Microtubule Inhibitor

Treatment (bintrafusp alfa, eribulin mesylate) for Breast Cancer

Phase 1
Waitlist Available
Led By Senthilkumar Damodaran
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 90 days post-treatment
Awards & highlights

Summary

This trial is studying the best dose and side effects of eribulin mesylate when given with M7824 for treating triple negative breast cancer.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 90 days post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 90 days post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events
Recommended phase II dose (RP2D)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (bintrafusp alfa, eribulin mesylate)Experimental Treatment2 Interventions
Patients receive bintrafusp alfa IV over 50-80 minutes on days 1, 15, and 29, and eribulin mesylate IV over 2-5 minutes on days 1, 8, 22, and 29. Treatment repeats every 42 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Eribulin
FDA approved
Bintrafusp alfa
Not yet FDA approved

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,962 Total Patients Enrolled
945 Trials studying Breast Cancer
1,543,964 Patients Enrolled for Breast Cancer
M.D. Anderson Cancer CenterLead Sponsor
3,039 Previous Clinical Trials
1,799,663 Total Patients Enrolled
148 Trials studying Breast Cancer
63,277 Patients Enrolled for Breast Cancer
Senthilkumar DamodaranPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
1,149 Total Patients Enrolled
~5 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top